ALPS Advisors’s iRadimed IRMD Stock Holding History

ALPS Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$478K	Sell	4,970 -1,483	-23%	-$148K	﹤0.01%	897
2025 Q4	$628K	Buy	6,453 +51	+0.8%	+$4.38K	﹤0.01%	672
2025 Q3	$456K	Sell	6,402 -575	-8%	-$38.3K	﹤0.01%	775
2025 Q2	$417K	Buy	6,977 +84	+1%	+$4.6K	﹤0.01%	739
2025 Q1	$362K	Sell	6,893 -410	-6%	-$23K	﹤0.01%	718
2024 Q4	$402K	Hold	7,303	–	–	﹤0.01%	691
2024 Q3	$367K	Sell	7,303 -697	-9%	-$32.2K	﹤0.01%	763
2024 Q2	$352K	Sell	8,000 -40	-0.5%	-$1.7K	﹤0.01%	730
2024 Q1	$354K	Buy	+8,040	New	+$355K	﹤0.01%	814

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's IRMD Position: Q1 2026 in Review

ALPS Advisors reduced its iRadimed (IRMD) stake by 23% in Q1 2026, selling an estimated $148K and leaving 4,970 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

ALPS Advisors first reported a position in IRMD in Q1 2024 and has held it in 9 quarters since. The position peaked at $628K in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

ALPS Advisors held 4,970 shares of iRadimed worth $478K as of Q1 2026.
ALPS Advisors sold 1,483 iRadimed shares in Q1 2026, an estimated $148K.
iRadimed made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #897 holding.
ALPS Advisors first reported a position in iRadimed in Q1 2024 and has held it in 9 quarters since.
ALPS Advisors's iRadimed position peaked at $628K in Q4 2025.
228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.